Skip to main content

Doxorubicin, AGEN1884, and AGEN2034 for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Trial Status: Active

This phase II trial studies how well doxorubicin together with AGEN1884 and AGEN2034 work in treating patients with soft tissue sarcoma that has spread to other places in the body (advanced or metastatic). Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as AGEN1884 and AGEN2034, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving doxorubicin, AGEN1884, and AGEN2034 may work better in treating patients with soft tissue sarcoma compared to doxorubicin alone.

Inclusion Criteria

  • Provision to sign and date the consent form
  • Stated willingness to comply with all study procedures and be available for the duration of the study
  • Have a histological diagnosis of advanced or metastatic soft tissue sarcoma (STS) (by local pathology review), not curable by surgery, for which treatment with doxorubicin is deemed appropriate by the investigator
  • Has one of the following histologies: * Synovial sarcoma * Malignant peripheral nerve sheath tumors * Dedifferentiated, pleomorphic or myxoid/round cell liposarcoma * Uterine or soft tissue leiomyosarcoma * Malignant phyllodes tumor * High grade undifferentiated pleomorphic sarcomas (HGUPS/malignant fibrous histiocytoma [MFH]) * Myxofibrosarcoma * Fibrosarcoma * Angiosarcoma * Spindle cell or undifferentiated sarcoma not otherwise specified (NOS) * Malignant myoepithelioma * Malignant solitary fibrous tumor/hemangiopericytoma * Epithelioid hemangioendothelioma * Any other histology or standard of care treatment not specifically addressed will be reviewed by the principal investigator and pathologist for final determination of eligibility
  • Have measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Tumors within a previously irradiated field will be designated as “nontarget” lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiotherapy
  • Have received 0 or 1 prior systemic therapies for metastatic sarcoma and NO prior anthracyclines or checkpoint inhibitors
  • Absolute neutrophil count (ANC) >= 1,000/mcL
  • Platelets >= 100,000/mcL
  • Hemoglobin >= 8 g/dL without erythropoietin (EPO) dependency
  • Serum creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 mL/min for subject with creatinine levels > 1.5 x institutional ULN * Creatinine clearance should be calculated per institutional standard
  • Serum total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN * Exception: Subjects with known history of Gilbert’s disease should be =< 1.5 x of the patient’s prior baseline
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases
  • Albumin >= 2.5 mg/dL
  • International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
  • Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Patients must consent and be willing to undergo tumor core needle biopsies at two timepoints: 1. baseline, 2. cycle 2 day 5; a third biopsy for off-study/progression is optional but advised. At least one tumor site must be amenable to biopsy in the judgment of the interventional radiologist
  • Female subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Females of child bearing potential that are sexually active must agree to either practice 2 medically accepted highly effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 120 days after the last dose of study drug. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year * Negative test for pregnancy is required of females of child-bearing potential. A female of child-bearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1. has not undergone a hysterectomy or bilateral oophorectomy; or 2. has not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months or 730 days.) * Conception while on treatment must be avoided
  • Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy. Prior history of vasectomy does NOT replace requirement for contraceptive use
  • Subjects must either possess or undergo placement of central venous catheter, including pheresis or trifusion catheter, peripherally inserted central catheter (PICC) line, or port

Exclusion Criteria

  • Prior therapy with anthracycline or checkpoint inhibitors
  • Hypersensitivity to doxorubicin or any excipients
  • Patients may not be receiving any other investigational agents (within 4 weeks prior to cycle 1, day 1)
  • Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to cycle 1, day 1 or has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier
  • Patient has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to cycle 1, day 1 or has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. Subjects with =< grade 2 neuropathy or alopecia are an exception to this criterion and may qualify for the study. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
  • Additional known malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer
  • Patients with underlying immune deficiency, chronic infections including human immunodeficiency virus (HIV), hepatitis, or tuberculosis (TB) or autoimmune disease
  • Patients with underlying hematologic issues including bleeding diathesis, known previous gastrointestinal (GI) bleeding requiring intervention within the past 6 months. Newly diagnosed pulmonary emboli or deep venous thrombosis must be clinically stable on anticoagulation regimen for >= 4 weeks as of cycle 1 day 1
  • Has known history of non-infectious pneumonitis that required oral corticosteroid therapy for resolution within 12 months prior to study entry, or evidence by imaging or symptoms of active non-infectious pneumonitis
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis or leptomeningeal disease. Subjects with previously treated brain metastases may participate provided they are stable based on the following: 1) magnetic resonance imaging (MRI) brain obtained during screening evaluations shows no radiographic evidence of progression or new lesions, 2) any neurologic symptoms have returned to baseline, 3) no requirement for steroids for at least 28 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability. Patients without a known history of brain metastases do not require screening brain MRI prior to study enrollment
  • Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
  • Any uncontrolled, intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia
  • Prolonged corrected QT (QTc) interval on screening electrocardiogram (EKG) > 475 ms
  • Ejection fraction < 50% by 2 dimensional (D) echocardiogram (ECHO) at screening
  • Any serious medical or psychiatric illness/condition including substance use disorders likely in the judgment of the Investigator(s) to interfere or limit compliance with study requirements/treatment, including New York Heart Association (NYHA) class II or greater heart disease
  • Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Had a previous severe hypersensitivity reaction to another monoclonal antibody
  • Primary or secondary immunodeficiency (including immunosuppressive disease, autoimmune disease [excluding hypothyroidism, insulin dependent diabetes mellitus, or vitiligo], or usage of immunosuppressive medications)


University of Colorado
Status: ACTIVE
Contact: Breelyn Ann Wilky
Phone: 303-724-6429


I. Determine the progression-free survival rate at 6 months of combination therapy with doxorubicin, zalifrelimab (AGEN1884), and balstilimab (AGEN2034) in anthracycline-naive patients with advanced or metastatic soft tissue sarcomas.


I. Determine the overall response rate, clinical benefit rate, overall survival, duration of response and toxicity profile of combination therapy with doxorubicin, AGEN1884, and AGEN2034 in anthracycline-naive patients with advanced or metastatic soft tissue sarcomas.


I. To obtain comprehensive immune and microenvironment profiling of tumor biopsies and peripheral blood in study patients pre-treatment and on-treatment and correlate with clinical response to therapy.


Patients receive balstilimab intravenously (IV) over 60 minutes on day 1, zalifrelimab IV over 90 minutes on day 1 of cycles 1, 3, 5, and 7, and doxorubicin via bolus infusion over 60 minutes on day 1 of cycles 2-7. Cycles with balstilimab repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Treatment repeats every 21 days for up to 4 cycles for zalifrelimab and up to 6 cycles for doxorubicin in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up within 14 days, and at 6, 12, and 24 weeks.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
University of Colorado

Principal Investigator
Breelyn Ann Wilky

  • Primary ID 19-0554
  • Secondary IDs NCI-2020-00728,
  • ID NCT04028063